Her Majesty The Queen presents cancer researchers with prize at Buckingham Palace 22 Feb 2024 Earlier today, researchers from The Institute of Cancer Research, London, received a prestigious Queen’s Anniversary Prize on behalf of the institute, in recognition of its transformational breast cancer research programme. Find out more Show/Hide
ICR welcomes recommendation of talazoparib for advanced breast cancer 19 Jan 2024 The Institute of Cancer Research, London, strongly welcomes the news that talazoparib (trade name Talzenna) has been recommended by NICE for the treatment of advanced breast cancer. Find out more Show/Hide
ICR welcomes FDA approval of first-in-class breast cancer drug 17 Nov 2023 The ICR strongly welcomes the news that a new targeted drug, capivasertib, has been approved by the US FDA for treating the most common type of advanced breast cancer. The drug was discovered by pharmaceutical company AstraZeneca following a programme of drug discovery research at the ICR in collaboration with Astex Pharmaceuticals. Find out more Show/Hide
New clinical trial guidelines set to increase transparency and support progress in developing new therapies 20 Oct 2023
‘Search and destroy’ treatment improves quality of life for patients with advanced prostate cancer 08 Sep 2023
ASCO 2023: New drug combination twice as effective for some ovarian cancer patients as next best treatment 04 Jun 2023
All patients’ cancers should be genetically profiled to improve care, say leading health experts 08 Aug 2022
AACR 2022: Team of scientists and clinicians wins global award for transforming breast cancer treatment 04 Apr 2022